Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY2944876

Recombinant protein · developed by OPKO Health

Phase 2 Most advanced trial (none active)
OPK Developer
1 Registered trials

What is LY2944876?

LY2944876 is a drug studied in type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Recombinant protein
Therapy area
Metabolic
Developer
OPKO Health, Inc. (OPK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
WG4ID2U7FT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02119819 Phase 2 Diabetes Mellitus, Type 2 Completed OPK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 2

More from OPKO Health

Follow OPK, the company behind LY2944876

See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OPK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.